[ Back to EurekAlert! ] Public release date: 7-Jul-2008
[ | E-mail Share Share ]

Contact: Andrew Hyde
press@plos.org
01-223-463-330
Public Library of Science

How can we overcome the barriers to treating drug-resistant TB?

Almost 1 in 20 cases of tuberculosis worldwide is resistant to multiple drugs (known as multidrug-resistant TB or MDR-TB) and the World Health Organization has called for a massive scale up in public health efforts to tackle these cases. In this week's PLoS Medicine, a group of MDR-TB experts outlines its recommendations on conducting research that would help in the scale up.

MDR-TB can be effectively treated using second-line TB drugs, though these drugs are more expensive, less potent, and less well tolerated than first-line drugs. Fewer than 2% of all patients with MDR-TB are receiving appropriate second-line treatment. The WHO has therefore called for a dramatic scale up of MDR-TB treatment as a routine component of TB control, setting a target of treating 1.6 million patients with MDR-TB by 2015. Pilot projects of MDR-TB management (known as "programmatic management of drug-resistant TB" or PMDT) in five low income settings showed treatment success rates of 59%-83%.

Frank Cobelens (KNVC Tuberculosis Foundation) and colleagues, writing on behalf of the Working Group on MDR-TB of the Stop TB Partnership, lay out their "prioritized research agenda." The agenda identifies the most important barriers to scaling up the treatment of MDR-TB and prioritizes the research questions to be addressed to overcome these barriers.

Their research priorities include:

With increasing recognition of drug-resistant TB worldwide, say Cobelens and colleagues, "the time has come to move PMDT in resource-limited settings beyond the limited, pilot project phase."

###

Citation: Cobelens FGJ, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, et al. (2008) Scaling up programmatic management of drug-resistant tuberculosis: A prioritized research agenda. PLoS Med 5(7): e150. doi:10.1371/journal.pmed.0050150.

IN YOUR ARTICLE, PLEASE LINK TO THIS URL, WHICH WILL PROVIDE ACCESS TO THE PUBLISHED PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050150

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-07-cobelens.pdf

CONTACT:

Frank Cobelens
KNCV Tuberculosis Foundation
The Hague, 2514 JD
Netherlands
+31 70 4270955
cobelensf@kncvtbc.nl



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.